{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:00:27Z","timestamp":1781643627932,"version":"3.54.5"},"reference-count":38,"publisher":"Radiation Research Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Radiation Research"],"published-print":{"date-parts":[[2019,1,29]]},"DOI":"10.1667\/rr15182.1","type":"journal-article","created":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T21:54:03Z","timestamp":1548798843000},"page":"271","source":"Crossref","is-referenced-by-count":26,"title":["Impact of Radiotherapy Concurrent with Anti-PD-1 Therapy on the Lung Tissue of Tumor-Bearing Mice"],"prefix":"10.1667","volume":"191","author":[{"given":"Feng","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Radiation and Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Radiation and Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Radiation and Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijing","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Radiation and Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingming","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Radiation and Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"You","sequence":"additional","affiliation":[{"name":"Department of Radiation and Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Biological Repositories, Zhongnan Hospital of Wuhan University, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conghua","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Radiation and Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1243","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"DJ Tandberg, BC Tong, BG Ackerson, et al.  \"Cancer.\"  124, \"Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: A comprehensive review.\" 667 (2018)","DOI":"10.1002\/cncr.31196"},{"key":"2","doi-asserted-by":"crossref","unstructured":"GP. Kalemkerian,  \"Semin Respir Crit Care Med.\"  37, \"Small cell lung cancer.\" 783 (2016)","DOI":"10.1055\/s-0036-1592116"},{"key":"3","doi-asserted-by":"crossref","unstructured":"B Sangro, D Martinez-Urbistondo, L Bester, et al.  \"Hepatology.\"  66, \"Prevention and treatment of complications of selective internal radiation therapy: Expert guidance and systematic review.\" 969 (2017)","DOI":"10.1002\/hep.29207"},{"key":"4","doi-asserted-by":"crossref","unstructured":"CA Hinojosa, NJ Soni, A Anzueto, et al.  \"Am J Respir Crit Care Med.\"  66, \"Prevention and treatment of complications of selective internal radiation therapy: Expert guidance and systematic review.\" 969 (2017)","DOI":"10.1002\/hep.29207"},{"key":"5","doi-asserted-by":"crossref","unstructured":"LB Marks, X Yu, Z Vujaskovic, et al.  \"Semin Radiat Oncol.\"  13, \"Radiation-induced lung injury.\" 333 (2003)","DOI":"10.1016\/S1053-4296(03)00034-1"},{"key":"6","doi-asserted-by":"crossref","unstructured":"V Mehta,  \"Int J Radiat Oncol Biol Phys.\"  63, \"Radiation pneumonitis and pulmonary fibrosis in non-small cell lung cancer: pulmonary function, prediction, and prevention.\" 5 (2005)","DOI":"10.1016\/j.ijrobp.2005.03.047"},{"key":"7","doi-asserted-by":"crossref","unstructured":"CB Simone,  \"Semin Radiat Oncol.\"  27, \"2nd. Thoracic radiation normal tissue injury.\" 370 (2017)","DOI":"10.1016\/j.semradonc.2017.04.009"},{"key":"8","doi-asserted-by":"crossref","unstructured":"J Chen, X Tian, Z Mei, et al.  \"Mol Immunol.\"  80, \"The effect of the TLR9 ligand CpG-oligodeoxynucleotide on the protective immune response to radiation-induced lung fibrosis in mice.\" 33 (2016)","DOI":"10.1016\/j.molimm.2016.11.001"},{"key":"9","doi-asserted-by":"crossref","unstructured":"MK Callahan, MA Postow, JD. Wolchok, et al.  \"Immunity.\"  44, \"cell co-receptors for cancer therapy.\" 1069 (2016)","DOI":"10.1016\/j.immuni.2016.04.023"},{"key":"38","doi-asserted-by":"crossref","unstructured":"SJ Shin, YK Jeon, PJ Kim, et al.  \"Ann Surg Oncol.\"  23, \"Clinicopathologic analysis of PD-L1 and PD-L2 expression in renal cell carcinoma: association with oncogenic proteins status.\" 694 (2016)","DOI":"10.1245\/s10434-015-4903-7"},{"key":"37","doi-asserted-by":"crossref","unstructured":"W Wang, K Wang, Z Chen, et al.  \"Oncotarget.\"  9, \"Immunoclassification characterized by CD8 and PD-L1 expression is associated with the clinical outcome of gastric cancer patients.\" 12164 (2018)","DOI":"10.18632\/oncotarget.24037"},{"key":"36","doi-asserted-by":"crossref","unstructured":"M Furue, T Ito, N Wada, et al.  \"Curr Oncol Rep.\"  20, \"Melanoma and immune checkpoint inhibitors.\" 29 (2018)","DOI":"10.1007\/s11912-018-0676-z"},{"key":"35","doi-asserted-by":"crossref","unstructured":"L Horn, DR Spigel, EE Vokes, et al.  \"J Clin Oncol.\"  35, \"Nivolumab versus docetaxel in previously treated patients with advanced non-small cell lung cancer: Two-year outcomes from two randomized, open-label, phase iii trials (CheckMate 017 and CheckMate 057).\" 3924 (2017)","DOI":"10.1200\/JCO.2017.74.3062"},{"key":"34","doi-asserted-by":"crossref","unstructured":"B Escudier, P Sharma, DF McDermott, et al.  \"Eur Urol.\"  72, \"CheckMate 025 randomized phase 3 study: Outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma.\" 962 (2017)","DOI":"10.1016\/j.eururo.2017.02.010"},{"key":"33","doi-asserted-by":"crossref","unstructured":"H Borghaei, L Paz-Ares, L Horn, et al.  \"N Engl J Med 2015;.\"  373, \"Nivolumab versus docetaxel in advanced nonsquamous non-small cell lung cancer.\" 1627 ()","DOI":"10.1056\/NEJMoa1507643"},{"key":"32","doi-asserted-by":"crossref","unstructured":"M Nishino, A Giobbie-Hurder, H Hatabu, et al.  \"J JAMA Oncol.\"  2, \"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: A systematic review and meta-analysis.\" 1607 (2016)","DOI":"10.1001\/jamaoncol.2016.2453"},{"key":"31","doi-asserted-by":"crossref","unstructured":"J Zhao, ED Yorke, L Li, et al.  \"Int J Radiat Oncol Biol Phys.\"  95, \"Simple factors associated with radiation-induced lung toxicity after stereotactic body radiation therapy of the thorax: A pooled analysis of 88 studies.\" 1357 (2016)","DOI":"10.1016\/j.ijrobp.2016.03.024"},{"key":"30","unstructured":"et al.  \"Zhongguo fei ai za zhi.\"  16, \"[Immunotherapy for non-small cell lung cancer\u2013novel approaches to improve patient outcome].\" C9 (2013)"},{"key":"29","doi-asserted-by":"crossref","unstructured":"N Shaverdian, AE Lisberg, K Bornazyan, et al.  \"Lancet Oncol.\"  18, \"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.\" 895 (2017)","DOI":"10.1016\/S1470-2045(17)30380-7"},{"key":"28","doi-asserted-by":"crossref","unstructured":"C Harada, T Kawaguchi, S Ogata-Suetsugu, et al.  \"Am J Respir Crit Care Med.\"  183, \"EGFR tyrosine kinase inhibition worsens acute lung injury in mice with repairing airway epithelium.\" 743 (2011)","DOI":"10.1164\/rccm.201002-0188OC"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Z Chen, X Shao, X Dou, et al.  \"PloS One.\"  11, \"Role of the mycoplasma pneumoniae\/interleukin-8\/neutrophil axis in the pathogenesis of pneumonia.\" e0146377 (2016)","DOI":"10.1371\/journal.pone.0146377"},{"key":"26","doi-asserted-by":"crossref","unstructured":"L Shi, L Chen, C Wu, et al.  \"Clin Cancer Res.\"  22, \"PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor.\" 1173 (2020)","DOI":"10.1158\/1078-0432.CCR-15-1352"},{"key":"25","doi-asserted-by":"crossref","unstructured":"C Vanpouille-Box, A Alard, MJ Aryankalayil, et al.  \"Nat Commun.\"  8, \"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity.\" 15618 (2017)","DOI":"10.1038\/ncomms15618"},{"key":"24","doi-asserted-by":"crossref","unstructured":"M Moradi, M Mojtahedzadeh, A Mandegari, et al.  \"Respir Med.\"  103, \"The role of glutathione-S-transferase polymorphisms on clinical outcome of ALI\/ARDS patient treated with N-acetylcysteine.\" 434 (2009)","DOI":"10.1016\/j.rmed.2008.09.013"},{"key":"23","doi-asserted-by":"crossref","unstructured":"S Tanaka, S Nishiumi, M Nishida, et al.  \"Clin Exp Immunol.\"  160, \"Vitamin K3 attenuates lipopolysaccharideinduced acute lung injury through inhibition of nuclear factorkappaB activation.\" 283 (2010)","DOI":"10.1111\/j.1365-2249.2009.04083.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"A Carotenuto, G Scalia, F Ausiello, et al.  \"J Neuroimmunol.\"  309, \"CD4\/CD8 ratio during natalizumab treatment in multiple sclerosis patients.\" 47 (2017)","DOI":"10.1016\/j.jneuroim.2017.05.006"},{"key":"21","doi-asserted-by":"crossref","unstructured":"ME Lacouture, JD Wolchok, G Yosipovitch, et al.  \"J Am Acad Dermatol.\"  71, \"Ipilimumab in patients with cancer and the management of dermatologic adverse events.\" 161 (2014)","DOI":"10.1016\/j.jaad.2014.02.035"},{"key":"20","doi-asserted-by":"crossref","unstructured":"VJ Shi, N Rodic, S Gettinger, et al.  \"JAMA Dermatol.\"  152, \"Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy.\" 1128 (2016)","DOI":"10.1001\/jamadermatol.2016.2226"},{"key":"19","doi-asserted-by":"crossref","unstructured":"RW Joseph, M Cappel, B Goedjen, et al.  \"Cancer Immunol Res.\"  3, \"Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy.\" 18 (2015)","DOI":"10.1158\/2326-6066.CIR-14-0134"},{"key":"18","doi-asserted-by":"crossref","unstructured":"KB Schaberg, RA Novoa, HA Wakelee, et al.  \"J Cutan Pathol.\"  43, \"Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy.\" 339 (2016)","DOI":"10.1111\/cup.12666"},{"key":"17","unstructured":"CL Toma, A Serbescu, M Alexe, et al.  \"Maedica (Buchar).\"  5, \"The bronchoalveolar lavage pattern in radiation pneumonitis secondary to radiotherapy for breast cancer.\" 250 (2010)"},{"key":"16","doi-asserted-by":"crossref","unstructured":"J Chen, Y Wang, Z Mei, et al.  \"J Radiat Res.\"  57, \"Radiation-induced lung fibrosis in a tumor-bearing mouse model is associated with enhanced type-2 immunity.\" 133 (2016)","DOI":"10.1093\/jrr\/rrv077"},{"key":"15","doi-asserted-by":"crossref","unstructured":"P Fluxa, D Rojas-Sepulveda, MA Gleisner, et al.  \"BMC Cancer.\"  18, \"High CD8(+) and absence of Foxp3(+) T lymphocytes infiltration in gallbladder tumors correlate with prolonged patients survival.\" 243 (2018)","DOI":"10.1186\/s12885-018-4147-6"},{"key":"14","doi-asserted-by":"crossref","unstructured":"SL Buchan, M Fallatah, SM Thirdborough, et al.  \"Clin Cancer Res.\"  24, \"PD-1 blockade and CD27 stimulation activate distinct transcriptional programs that synergize for CD8(+) T-cell-driven antitumor immunity.\" 2383 (2018)","DOI":"10.1158\/1078-0432.CCR-17-3057"},{"key":"13","doi-asserted-by":"crossref","unstructured":"S Ueha, S Yokochi, Y Ishiwata, et al.  \"Cancer Immunol Res.\"  3, \"Robust antitumor effects of combined anti-CD4-depleting antibody and anti-PD-1\/PD-L1 immune checkpoint antibody treatment in mice.\" 631 (2015)","DOI":"10.1158\/2326-6066.CIR-14-0190"},{"key":"12","doi-asserted-by":"crossref","unstructured":"S Du, L Zhou, GS Alexander, et al.  \"J Thorac Oncol.\"  13, \"PD-1 modulates radiation-induced cardiac toxicity through cytotoxic T lymphocytes.\" 510 (2018)","DOI":"10.1016\/j.jtho.2017.12.002"},{"key":"11","doi-asserted-by":"crossref","unstructured":"K Haratani, H Hayashi, Y Chiba, et al.  \"JAMA Oncol.\"  4, \"Association of immune-related adverse events with nivolumab efficacy in non-small cell lung cancer.\" 374 (2018)","DOI":"10.1001\/jamaoncol.2017.2925"},{"key":"10","doi-asserted-by":"crossref","unstructured":"T Uemura  and T. Hida  \"J Thorac Dis.\"  10, \"Durvalumab showed long and durable effects after chemoradiotherapy in stage III non-small cell lung cancer: results of the PACIFIC study.\" S1108 (2018)","DOI":"10.21037\/jtd.2018.03.180"}],"container-title":["Radiation Research"],"original-title":[],"deposited":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T19:18:24Z","timestamp":1564600704000},"score":1,"resource":{"primary":{"URL":"https:\/\/bioone.org\/journals\/radiation-research\/volume-191\/issue-3\/RR15182.1\/Impact-of-Radiotherapy-Concurrent-with-Anti-PD-1-Therapy-on\/10.1667\/RR15182.1.full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,29]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1667\/rr15182.1","relation":{},"ISSN":["0033-7587"],"issn-type":[{"value":"0033-7587","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1,29]]}}}